Evofem Biosciences, Inc. (EVFM) News
Filter EVFM News Items
EVFM News Results
|Loading, please wait...|
EVFM News Highlights
- For EVFM, its 30 day story count is now at 3.
- Over the past 9 days, the trend for EVFM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about EVFM are DRUG.
Latest EVFM News From Around the Web
Below are the latest news stories about Evofem Biosciences Inc that investors may wish to consider to help them evaluate EVFM as an investment opportunity.
Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022
Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m. PT).
Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious Disease Product" (QIDP) Designation to EVO100 (the investigational name for Phexxi® (lactic acid, citric acid and potassium bitartrate)) for the prevention of urogenital chlamydia infection in women, a potential new indication in late stage clinical development. Chlamydia is the most frequently reported bacterial infection in the United States.
Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows:
La Jolla, CA, based Investment company Callan Capital, LLC (Current Portfolio) buys Schwab Fundamental U.S.
Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).
Today, investors in women''s health company Evofem Biosciences and EVFM stock are dancing, following revised birth control regulations.
Evofem Biosciences <
Micro-cap stock Evofem Biosciences (EVFM) has gained ~30.0% on above-average volume after the company highlighted how a newly issued guidance from the U.S
Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading higher after the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor issued updated guidance related to contraceptive access. The new guidance specifies that most insurers and pharmacy benefit managers (PBMs) must provide coverage, with no out-of-pocket costs to women, for FDA-approved contraceptive products, like Phexxi, prescribed by healthcare providers. "We believe this is a huge step forward toward ens
Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women
Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access.